Avid Bioservices Inc (CDMO)

[BioBS2012]

PPHM Strategy - IMO

I know many here get disappointed whenever pre-clinical results are announced. IMO PPHM is following a very smart strategy. Using approved (soon to be approved) chemo and I/O drugs to generate pre-clinical data while Phase III NSCLC progresses. The results of all the pre-clinical studies to date show synergies between the chemo or I/O compounds in well defined animal models.
Once BAVI is approved in NSCLC, this preclinical data will help drive the off-label applications IMO.
Showing synergies with multiple drugs acting via vastly different mechanisms demonstrates the broad applicability of BAVI. The current and ongoing pre-clinical work can be viewed as continuation of the education of the scientific community. By the time BAVI is approved for NSCLC there will be enough data and information out there that has been presented and published to make people comfortable with what BAVI can do - not just in NSCLC but across the broad spectrum of solid tumors - much like what BMY and MRK have been able to accomplish with the tremendous resources that they have at their disposal.
Yes, the going maybe a bit slow for many on here, but progress is being made and it is solid progress - IMO.
Bricks continue to be laid and the BAVI wall is getting built - slowly but steadily.

Do your own DUE DILIGENCE
DO NOT rely on what DEW DILIGENCE says !!